Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
180 participants
OBSERVATIONAL
2017-01-01
2018-03-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
High-sensitivity C-reactive Protein and United Kingdom Prospective Diabetes Study (UKPDS) Risk Score in Type 2 Diabetes
NCT01099865
of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).
NCT00925717
Type 2 Diabetes in Fayoum
NCT03683784
Evaluation of Innovated Screening Tools for Type 2 Diabetes Among Chinese Population(SENSIBLE STUDY I)
NCT03025919
Screening for Undiagnosed Type 2 Diabetes in New Classes of Subjects at High Risk
NCT00520962
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prediabetics
Ages ranging from 18 to 60 years old,males and females were included . A fasting blood glucose level (100 to 125 mg/dL). or A 2-hour blood glucose level (140 to 199 mg/dL) .or Hb A1C 5.7% to 6.4%.
No interventions assigned to this group
Newly diagnosed type 2 diabetes
Ages ranging from 18 to 60 years old,males and females were included Newly diagnosed type 2 diabetes: (maximum within one month from diagnosis) A fasting blood glucose level \>126 mg/dl A 2-hour blood glucose level \> 200 mg/d Hb A1C \> 6.5%
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A fasting blood glucose level (100 to 125 mg/dL). or
* A 2-hour blood glucose level (140 to 199 mg/dL) .or
* Hb A1C 5.7% to 6.4%.
* Newly diagnosed type 2 diabetes: (maximum within one month from diagnosis)
* A fasting blood glucose level \>126 mg/dl
* A 2-hour blood glucose level \> 200 mg/dl
* Hb A1C \> 6.5%
Exclusion Criteria
* Patients who have recent infection.
* Patients with acute inflammatory diseases as autoimmune diseases.
* Patients with malignancy or on chemotherapy.
* Patients with acute or chronic liver or renal diseases
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fayoum University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Abdelkawi Hammad
Lecturer of internal medicine
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D84
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.